Renal cell carcinoma medical therapy

Revision as of 20:02, 11 January 2014 by Rim Halaby (talk | contribs)
Jump to navigation Jump to search

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Renal cell carcinoma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Renal cell carcinoma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural history, Complications and Prognosis

Diagnosis

Staging

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Renal cell carcinoma medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Renal cell carcinoma medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Renal cell carcinoma medical therapy

CDC on Renal cell carcinoma medical therapy

Renal cell carcinoma medical therapy in the news

Blogs on Renal cell carcinoma medical therapy

Directions to Hospitals Treating Renal cell carcinoma

Risk calculators and risk factors for Renal cell carcinoma medical therapy

Overview

Small Renal Masses

Partial Nephrectomy

Small renal masses are defined as masses that are less than or equal to 4 cm on CT scan enhancement. Optimal management of small renal masses includes open or laparoscopic partial nephrectomy.[1][2][3] Partial nephrectomy is characterized by a low-complication rate. Most common complications include urinary leak and hemorrhage that occur in 3-5% and 1%, respectively.[1][2][3] Partial nephrectomy is associated with less chronic renal failure (CRF) than with radical nephrectomy, with a rate of CRF ranging between 5-20% and 36-65%, respectively.[4]

Special consideration must be made for patient subgroups, including the elderly and those with high surgical risk. Because the average growth rate of small renal tumors is considered small - approaching 0.28 cm/year and a 1% rate of metastasis - partial nephrectomy may be spared in these patients.[5][3]

Probe-Based Thermal Ablation

Percutaneous or laparoscopic probe-based thermal ablation is a new management method for patients with small renal masses. The technique utilizes extreme temperatures, such as cryoablation or radiofrequency ablation.[6][7] Thermal ablation is still considered inferior to partial nephrectomy due to the following considerations:

  • Difficulty in ablation of large (>3.5 cm) tumors[3]
  • Higher local recurrence rate in thermal ablation[8]
  • Ill-defined radiographic parameters for success in thermal ablation[9]
  • Post-ablation surgery may be compromised due to presence of ablation fibrotic reactions[3]
  • Unavailable long-term data on patients undergoing ablation

Advanced Renal Tumors

References

  1. 1.0 1.1 Gill IS, Kavoussi LR, Lane BR, Blute ML, Babineau D, Colombo JR; et al. (2007). "Comparison of 1,800 laparoscopic and open partial nephrectomies for single renal tumors". J Urol. 178 (1): 41–6. doi:10.1016/j.juro.2007.03.038. PMID 17574056.
  2. 2.0 2.1 Lane BR, Novick AC, Babineau D, Fergany AF, Kaouk JH, Gill IS (2008). "Comparison of laparoscopic and open partial nephrectomy for tumor in a solitary kidney". J Urol. 179 (3): 847–51, discussion 852. doi:10.1016/j.juro.2007.10.050. PMID 18221958.
  3. 3.0 3.1 3.2 3.3 3.4 Rini BI, Campbell SC, Escudier B (2009). "Renal cell carcinoma". Lancet. 373 (9669): 1119–32. doi:10.1016/S0140-6736(09)60229-4. PMID 19269025.
  4. Huang WC, Levey AS, Serio AM, Snyder M, Vickers AJ, Raj GV; et al. (2006). "Chronic kidney disease after nephrectomy in patients with renal cortical tumours: a retrospective cohort study". Lancet Oncol. 7 (9): 735–40. doi:10.1016/S1470-2045(06)70803-8. PMC 2239298. PMID 16945768.
  5. Chawla SN, Crispen PL, Hanlon AL, Greenberg RE, Chen DY, Uzzo RG (2006). "The natural history of observed enhancing renal masses: meta-analysis and review of the world literature". J Urol. 175 (2): 425–31. doi:10.1016/S0022-5347(05)00148-5. PMID 16406965.
  6. Gill IS, Novick AC, Meraney AM, Chen RN, Hobart MG, Sung GT; et al. (2000). "Laparoscopic renal cryoablation in 32 patients". Urology. 56 (5): 748–53. PMID 11068292.
  7. Gill IS, Remer EM, Hasan WA, Strzempkowski B, Spaliviero M, Steinberg AP; et al. (2005). "Renal cryoablation: outcome at 3 years". J Urol. 173 (6): 1903–7. doi:10.1097/01.ju.0000158154.28845.c9. PMID 15879772.
  8. Kunkle DA, Egleston BL, Uzzo RG (2008). "Excise, ablate or observe: the small renal mass dilemma--a meta-analysis and review". J Urol. 179 (4): 1227–33, discussion 1233-4. doi:10.1016/j.juro.2007.11.047. PMID 18280512.
  9. Weight CJ, Kaouk JH, Hegarty NJ, Remer EM, O'Malley CM, Lane BR; et al. (2008). "Correlation of radiographic imaging and histopathology following cryoablation and radio frequency ablation for renal tumors". J Urol. 179 (4): 1277–81, discussion 1281-3. doi:10.1016/j.juro.2007.11.075. PMID 18280507.